Trevi Therapeutics, Inc. Common Stock (TRVI) Stock
NASDAQ · TRVI
14.95
Fundamentals
Market cap
$2.13B
Price / Earnings ratio
-42.4x
Price / Sales ratio
N/A
Price / Book ratio
6.7x
Return on assets
-0.2%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Trevi Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees34
CEOMs. Jennifer L. Good
IPO DateMay 2, 2019
HeadquartersNew Haven, CT
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Jennifer L. Good | Co-Founder, CEO, President, & Director | 1965 |
| Dr. James V. Cassella Ph.D. | Chief Development Officer | 1955 |
| Mr. Farrell Simon Pharm.D. | Chief Commercial Officer | — |
| Dr. Thomas R. Sciascia M.D. | Co-Founder & Chief Scientific Officer | 1953 |
| Mr. David C. Hastings CPA | Chief Financial Officer & Principal Financial Officer | 1961 |
| Mr. Christopher Galletta | Controller & Chief Accounting Officer | 1978 |
| Katie McManus | Communications Manager | — |
Fundamentals
Valuation
Market cap$2.13B
Price-to-sales ratioN/A
Price-to-book value6.74
Price-earnings ratio-42.40
Return on Equity-25.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.34
Income Statement
Average volume1,521,171
EBITDA$-45.54M
1 year high (52w)$20.22
1 year low (52w)$8.03
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



